journal
https://read.qxmd.com/read/38174978/growth-hormone-and-radiation-therapy-friend-foe-or-both
#21
REVIEW
Verónica A Bahamondes Lorca, Shiyong Wu
Radiotherapy is one of the major options currently for cancer treatment. Radiotherapy causes cellular damage inducing cell death, which is expected to be selective for tumor cells. However, side effects that alter the surrounding normal tissue are often hard to be avoided. When radiation involves the hypothalamic-pituitary axis, growth hormone deficiency (GHD) is frequently induced, causing developmental and metabolic-related diseases in childhood cancer survivors. Growth hormone (GH) replacement therapy has been used for these patients and has been shown to be safe in general...
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38376827/subgroup-analysis-of-steadily-increased-trends-in-medullary-thyroid-carcinoma-incidence-and-mortality-in-the-united-states-2000-2020-a-population-based-retrospective-cohort-study
#22
JOURNAL ARTICLE
Zixia Tao, Xianzhao Deng, Bomin Guo, Zheng Ding, You-Ben Fan
The incidence rate of medullary thyroid carcinoma (MTC) continues to grow, along with its mortality rate in the United States. However, the subgroup trends in medullary thyroid carcinoma have not yet been established. This population-based retrospective cohort study was based on the Surveillance, Epidemiology, and End Results-17/12 registry database. Subgroup analysis was performed through clinicopathological and treatment-related characteristics. Annual average percent change (AAPC) was calculated using joinpoint regression analysis...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38363202/multivariable-model-versus-ajcc-staging-system-cancer-specific-survival-predictions-in-adrenocortical-carcinoma
#23
JOURNAL ARTICLE
Letizia Maria Ippolita Jannello, Simone Morra, Lukas Scheipner, Andrea Baudo, Carolin Siech, Mario de Angelis, Nawar Touma, Zhe Tian, Jordan A Goyal, Stefano Luzzago, Francesco Alessandro Mistretta, Mattia Luca Piccinelli, Fred Saad, Felix K H Chun, Alberto Briganti, Sascha Ahyai, Luca Carmignani, Nicola Longo, Ottavio De Cobelli, Gennaro Musi, Pierre I Karakiewicz
We developed a novel contemporary population-based model for predicting cancer-specific survival (CSS) in adrenocortical carcinoma (ACC) patients and compared it with the established 8th edition of the American Joint Committee on Cancer staging system (AJCC). Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified 1056 ACC patients. Univariable Cox regression model addressed CSS. Harrell's concordance index (c-index) quantified accuracy after 2000 bootstrap resamples for internal validation...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38329269/transformation-of-g1-g2-neuroendocrine-tumors-to-neuroendocrine-carcinomas-following-peptide-receptor-radionuclide-therapy
#24
JOURNAL ARTICLE
Igryl S Cordero-Hernandez, Alicia C Ross, Arvind Dasari, Daniel M Halperin, Beth A Chasen, James C Yao
We observed that some patients with well-differentiated neuroendocrine tumors (NETs) who received peptide receptor radionuclide therapy (PRRT) with Lutetium-177(177Lu) DOTATATE developed rapid disease progression with biopsy-proven histologic transformation to neuroendocrine carcinoma (NEC), an outcome that has not been previously described. Therefore, we conducted a retrospective review of all patients with well-differentiated G1-G2 NETs who received at least one cycle of PRRT with (177Lu) DOTATATE at our center from January 2019 to December 2020...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38108666/beyond-the-three-p-s-adrenal-involvement-in-men1
#25
JOURNAL ARTICLE
Uriel Clemente-Gutierrez, Carolina R C Pieterman, Michael S Lui, Thomas Szabo Yamashita, Andrés Tame-Elorduy, Bernice L Huang, Aditya S Shirali, Derek J Erstad, Jeffrey E Lee, Sarah B Fisher, Paul H Graham, Elizabeth G Grubbs, Steven G Waguespack, Chaan S Ng, Nancy Perrier
Adrenal lesions (ALs) are often detected in patients with multiple endocrine neoplasia type 1 (MEN1). However, they are not well described in MEN1, making their clinical management unclear. This study examined the prevalence and outcomes of ALs found in MEN1. We performed a retrospective chart review of patients diagnosed with MEN1 from 1990 to 2021. ALs were diagnosed using abdominal or thoracic imaging and classified as being unilateral or bilateral, having single or multiple nodules, and as having diffuse enlargement or not...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38015791/genomic-profiling-of-primary-and-metastatic-thyroid-cancers
#26
JOURNAL ARTICLE
Valdemar Máximo, Miguel Melo, Yingjie Zhu, Andrea Gazzo, Manuel Sobrinho Simões, Arnaud Da Cruz Paula, Paula Soares
The genetic repertoire of primary thyroid cancers (TCs) is well documented, but there is a considerable lack of molecular profiling in metastatic TCs. Here, we retrieved and analyzed the molecular and clinical features of 475 primary and metastatic TCs subjected to targeted DNA sequencing, from the cBioPortal database. The cohort included primary and metastatic samples from 276 papillary thyroid carcinomas (PTCs), 5 follicular thyroid carcinomas, 22 Hürthle cell carcinomas (HCCs), 127 poorly differentiated thyroid carcinomas (PDTCs), 30 anaplastic thyroid carcinomas (ATCs) and 15 medullary thyroid carcinomas...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38284820/erratum-mutational-landscape-of-non-functional-adrenocortical-adenomas
#27
Luming Wu, Jing Xie, Yan Qi, Tingwei Su, Lei Jiang, Weiwei Zhou, Yiran Jiang, Cui Zhang, Xu Zhong, Yanan Cao, Weiqing Wang
No abstract text is available yet for this article.
January 29, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38289290/bioengineered-in-vitro-three-dimensional-tumor-models-in-endocrine-cancers
#28
REVIEW
Aleksander Skardal, Hemamylammal Sivakumar, Marco Rodriguez, Liudmila Popova, Priya Dedhia
Endocrine tumors are a heterogeneous cluster of malignancies that originate from cells that can secrete hormones. Examples include, but are not limited to, thyroid cancer, adrenocortical carcinoma, and neuroendocrine tumors. Many endocrine tumors are relatively slow to proliferate, and as such, they often do not respond well to common anti-proliferative chemotherapies. Therefore, increasing attention has been given to targeted therapies and immunotherapies in these diseases. However, in contrast to other cancers, many endocrine tumors are relatively rare, and as a result, less is understood about their biology, including specific targets for intervention...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38261313/efficacy-and-safety-of-pralsetinib-in-chinese-advanced-ret-mutant-medullary-thyroid-cancer-patients
#29
JOURNAL ARTICLE
Xiangqian Zheng, Meiyu Fang, Yun Fan, Yuping Sun, Meili Sun, Ankui Yang, Bin Zhang, Qinjiang Liu, Hui Liu, Xiaohong Zhou, Tao Huang, Jianwu Qin, Zhaohui Wang, Mengmeng Qin, Zhenwei Shen, Sheng Yao, Jason Yang, Yu Wang, Ming Gao
Pralsetinib has been proven efficacious activity in a variety of solid tumors including medullary thyroid cancer (MTC) in the phase 1/2 global ARROW study (BLU-667-1101; NCT03037385). We assessed the safety and efficacy of pralsetinib in Chinese ad-vanced RET-mutant MTC patients. In the extension cohort of ARROW, adult patients with advanced MTC who had not received systemic therapy (except for cytotoxic chem-otherapy), treated with pralsetinib (400 mg once daily, orally). The primary endpoints were blinded independent central reviewed (BICR) objective response rate (ORR), and safety...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38252063/clinical-utility-of-plasma-cell-free-dna-in-pancreatic-neuroendocrine-neoplasms
#30
JOURNAL ARTICLE
Darren Cowzer, Ronak H Shah, Joanne F Chou, Ritika Kundra, Sippy Punn, Laura Fiedler, April DeMore, Marinela Capanu, Michael F Berger, Diane Reidy-Lagunes, Nitya Raj
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well differentiated intermediate grade disease (13/25; 52%)...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38224097/lamin-b1-a-novel-biomarker-in-adult-and-pediatric-adrenocortical-carcinoma
#31
JOURNAL ARTICLE
Yihao Chen, Jiahong Chen, Yongcheng Shi, Xiaohui Ling, Shumin Fang, Chuanfan Zhong, Fengping Liu, Weide Zhong, Xuecheng Bi, Zhong Dong, Jianming Lu
Adrenocortical carcinoma (ACC) is a malignancy with a poor prognosis and high mortality rate. A high tumor mutational burden (TMB) has been found to be associated with poor prognosis in ACC. Thus, exploring ACC biomarkers based on TMB holds significant importance for patient risk stratification. In our research, we utilized weighted gene coexpression network analysis (WGCNA) and an assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) to identify genes associated with TMB. Through the comprehensive analysis of various public datasets, Lamin B1 (LMNB1) was identified as a biomarker associated with a high TMB and low chromatin accessibility...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38214937/immunophenotyping-with-high-dimensional-flow-cytometry-identifies-treg-cell-subsets-associated-with-recurrence-in-papillary-thyroid-carcinoma
#32
JOURNAL ARTICLE
Sijin Li, Zhen Chen, Mengchu Liu, Liang Li, Wensong Cai, Zhe-Xiong Lian, Haixia Guan, Bo Xu
The activation of Treg cell subsets is critical for the prognosis of tumor patients; however, their heterogeneity and disease association in papillary thyroid carcinoma (PTC) need further investigation. We performed high-dimensional flow cytometry for immunophenotyping on thyroid tissues and matched peripheral blood samples from patients with multinodular goiters or PTC. We analyzed Treg cell phenotype and compared the recurrence-free survival of PTC patients with different Treg cell subset characteristics using TCGA...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38214923/alternative-schedule-of-temozolomide-capecitabine-in-neuroendocrine-neoplasms
#33
JOURNAL ARTICLE
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
The chemotherapy regimen capecitabine/temozolomide (CAPTEM) is routinely used in neuroendocrine tumors (NET), with antitumor activity particularly demonstrated in pancreatic or high-grade neuroendocrine neoplasms (NEN). However, different dosing regimens are used, and the optimal schedule remains to be defined. This single-center retrospective analysis assessed the efficacy and safety of CAPTEM in patients with NEN using a schedule starting both compounds simultaneously (temozolomide on days 1-5 and capecitabine on days 1-14 of a 28 day cycle) rather than sequentially...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38174975/sexual-dimorphism-in-medullary-thyroid-cancer-aggressiveness
#34
JOURNAL ARTICLE
Andreas Machens, Kerstin Lorenz, Frank Weber, Henning Dralle
Thyroid cancer is the only nonreproductive cancer with striking female predominance, although men with thyroid cancer develop more aggressive disease. This study aimed to quantify sex-specific differences in medullary thyroid cancer (MTC) spread after controlling for primary thyroid tumor size.Included in this retrospective analysis were all patients with unilateral solitary MTC who underwent initial neck surgery at a tertiary referral center. A total of 565 patients, 255 men and 310 women, were identified, of whom 467 had sporadic and 98 hereditary MTC...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38031994/response-to-letter-to-the-editor-regarding-risk-of-complications-after-core-needle-biopsy-in-pheochromocytoma-paraganglioma
#35
JOURNAL ARTICLE
Liang Zhang, Tobias Åkerström, Kazhan Mollazadegan, Felix Beuschlein, Karel Pacak, Britt Skogseid, Joakim Crona
No abstract text is available yet for this article.
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38031993/core-needle-biopsy-in-pheochromocytoma-paraganglioma-should-it-be-considered
#36
JOURNAL ARTICLE
Gergely Huszty, Peter Igaz
No abstract text is available yet for this article.
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/37955319/false-positive-results-for-pheochromocytoma-associated-with-norepinephrine-reuptake-blockade
#37
JOURNAL ARTICLE
Robin Schürfeld, Christina Pamporaki, Mirko Peitzsch, Nada Rayes, Osama Sabri, Silvio Rohm, Ronald Biemann, Benjamin Sandner, Anke Tönjes, Graeme Eisenhofer
Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma. False-positive results remain a problem, particularly in patients taking norepinephrine reuptake-blocking drugs. Therefore, in this retrospective observational study, we measured plasma metanephrines and methoxytyramine in 61 patients taking norepinephrine reuptake blockers (tricyclic antidepressants or serotonin-norepinephrine reuptake inhibitors) and 17 others taking selective serotonin reuptake inhibitors, all without pheochromocytoma/paraganglioma...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/37943630/impact-of-the-pi3k-alpha-inhibitor-alpelisib-on-everolimus-resistance-and-somatostatin-receptor-expression-in-an-orthotopic-pancreatic-nec-xenograft-mouse-model
#38
JOURNAL ARTICLE
Ajay-Mohan Mohan, Sonal Prasad, Fabian Schmitz-Peiffer, Catharina Lange, Mathias Lukas, Eva J Koziolek, Jakob Albrecht, Daniel Messroghli, Ulrike Stein, Matthias Ilmer, Katharina Wang, Laura Schober, Astrid Reul, Julian Maurer, Juliane Friemel, Achim Weber, Richard A Zuellig, Constanze Hantel, Ralph Fritsch, Martin Reincke, Karel Pacak, Ashley B Grossman, Christoph J Auernhammer, Felix Beuschlein, Winfried Brenner, Nicola Beindorff, Svenja Nölting
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation, most patients develop resistance within 1 year. Our aim was to overcome resistance to everolimus by additional treatment with the PI3K-alpha inhibitor alpelisib in an everolimus-resistant orthotopic pancreatic neuroendocrine carcinoma xenograft mouse model. Female SCID mice underwent laparoscopic pancreatic transplantation of everolimus-sensitive (BON1KDMSO) or everolimus-resistant (BON1RR2) NET cells...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/37877767/autocrine-paracrine-growth-hormone-in-cancer-progression
#39
JOURNAL ARTICLE
Xi Zhang, Vijay Pandey, Vipul Bhardwaj, Tao Zhu, Peter E Lobie
It is now apparent that growth hormone (GH), an anterior pituitary hormone predominantly regulating postnatal somatic growth and metabolism, is also expressed in extrapituitary tissues. An extrapituitary synthetic site of GH that has garnered interest is the de novo or enhanced expression of GH in carcinoma or other cancers. In a number of cancers, including carcinoma of the mammary gland, endometrium, liver, prostate, and colon, the expression of GH is independently associated with more advanced clinicopathologic parameters of the cancer...
January 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38117915/impact-of-sex-on-treatment-decisions-and-outcome-in-patients-with-neuroendocrine-neoplasms
#40
JOURNAL ARTICLE
Julia Beck, Alexander Siebenhüner, Damian Wild, Emanuel Christ, Julie Refardt
The influence of sex on neuroendocrine neoplasms (NENs) has been scarcely investigated. Thus, this study aimed to compare tumor characteristics, treatment decisions, and overall survival in patients with NENs, stratified by sex. The retrospective analysis of the SwissNET cohort covered NENs of gastroenteropancreatic, pulmonary, or unknown origin from 07/14 - 09/22. The analysis included 1985 patients (46% female and 54% male). Male patients presented with higher staging at time of diagnosis and with more lymph node- and bone-metastases...
December 1, 2023: Endocrine-related Cancer
journal
journal
32030
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.